ASP Isotopes Financials
ASP Isotopes (ASPI) reported $30.9M in revenue over the twelve months to Jun 30, 2026, up 573.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
ASPI is in a capital-funded buildout: new equity is expanding the balance sheet faster than revenue can absorb costs.
Over the last year, financing inflows of$371.6M pushed cash to$279.6M even as operations consumed cash. Because shares outstanding rose to 110.8M while long-term debt stayed near$1.5M , that liquidity came mainly from selling ownership rather than borrowing. The balance sheet became more liquid without becoming more leveraged.
The business now looks more like a funded build phase than a self-financing operation: total assets reached
Scale has not yet produced operating leverage. Revenue expanded from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of ASP Isotopes's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
ASP Isotopes's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 20/100.
ASP Isotopes's revenue surged 475.5% year-over-year to $23.8M, reflecting rapid business expansion. This strong growth earns a score of 99/100.
ASP Isotopes carries a low D/E ratio of 0.01, meaning only $0.01 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 88/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 12.23, ASP Isotopes holds $12.23 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 98/100.
ASP Isotopes's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 3/100.
ASP Isotopes posts a -78.3% return on equity (ROE), meaning it loses $78 for every $100 of shareholders' equity. This results in a returns score of 29/100. This is down from -67.7% the prior year.
ASP Isotopes scores 1.40, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($594.8M) relative to total liabilities ($235.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ASP Isotopes passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
ASP Isotopes reported a net loss of $159.8M while operations used $37.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
ASP Isotopes reported an operating loss of $59.9M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
ASP Isotopes generated $23.8M in revenue in fiscal year 2025. This represents an increase of 475.5% from the prior year.
ASP Isotopes's EBITDA was -$58.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 124.1% from the prior year.
ASP Isotopes reported -$159.8M in net income in fiscal year 2025. This represents a decrease of 393.0% from the prior year.
ASP Isotopes earned -$2.11 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 234.9% from the prior year.
Cash & Balance Sheet
ASP Isotopes recorded an outflow of $47.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 79.9% from the prior year.
ASP Isotopes held $279.6M in cash against $1.5M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
ASP Isotopes's gross margin was 14.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 24.3 percentage points from the prior year.
ASP Isotopes's ROE was -78.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 10.6 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
ASP Isotopes invested $12.4M in research and development in fiscal year 2025. This represents an increase of 293.7% from the prior year.
ASP Isotopes invested $9.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 0.2% from the prior year.
Not reported for fiscal year 2025.
ASPI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M+22.6% | $4.2M-74.9% | $16.7M+240.7% | $4.9M+308.1% | $1.2M+8.7% | $1.1M-7.7% | $1.2M+9.7% | $1.1M |
| Cost of Revenue | $3.6M+44.9% | $2.5M-82.8% | $14.6M+226.4% | $4.5M+613.5% | $626K-19.2% | $775K+31.7% | $589K-25.9% | $794K |
| Gross Profit | $1.5M-11.2% | $1.7M-20.0% | $2.1M+392.2% | $423K-26.0% | $572K+74.9% | $327K-46.0% | $605K+105.8% | $294K |
| R&D Expenses | $6.8M+29.7% | $5.3M-23.2% | $6.8M+121.1% | $3.1M+252.1% | $880K-42.5% | $1.5M+8.0% | $1.4M+36.9% | $1.0M |
| SG&A Expenses | $28.9M+35.5% | $21.3M+21.4% | $17.5M+42.7% | $12.3M+5.4% | $11.7M+72.8% | $6.7M-44.7% | $12.2M+159.8% | $4.7M |
| Operating Income | -$34.2M-37.4% | -$24.9M+0.5% | -$25.0M-67.2% | -$15.0M-25.0% | -$12.0M-50.5% | -$8.0M-4.0% | -$7.6M-40.8% | -$5.4M |
| Interest Expense | $1.8M+2.6% | $1.7M | $0 | $0-100.0% | $3K-59.6% | $7K+110.3% | -$65K | $0 |
| Income Tax | -$97K-212.9% | -$31K-116.8% | $184K+150.4% | $74K-22.5% | $95K+233.8% | -$71K-146.3% | $153K+1930.6% | -$8K |
| Net Income | -$34.0M-377.4% | -$7.1M+88.8% | -$63.3M-391.2% | -$12.9M+82.8% | -$75.2M-788.2% | -$8.5M+8.2% | -$9.2M-25.4% | -$7.4M |
| EPS (Diluted) | -$0.27-350.0% | -$0.06 | -$0.84-460.0% | -$0.15+85.4% | -$1.03-758.3% | -$0.12+7.7% | -$0.13-8.3% | -$0.12 |
ASPI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $572.0M-2.7% | $587.7M+18.0% | $498.0M+120.5% | $225.9M+66.2% | $135.9M+49.6% | $90.9M-3.7% | $94.3M+12.2% | $84.1M |
| Current Assets | $272.2M-11.8% | $308.7M-22.8% | $399.9M+129.8% | $174.0M+71.3% | $101.6M+72.1% | $59.0M-10.2% | $65.7M+17.2% | $56.1M |
| Cash & Equivalents | $219.6M+5.9% | $207.3M-25.8% | $279.6M+145.5% | $113.9M+68.3% | $67.7M+20.9% | $56.0M-9.6% | $61.9M+20.0% | $51.6M |
| Inventory | $1.5M+11.5% | $1.4M+24.7% | $1.1M-20.0% | $1.4M+31.2% | $1.0M+205.1% | $343K+419.2% | $66K-22.2% | $85K |
| Accounts Receivable | $3.0M+27.1% | $2.4M+122.0% | $1.1M-93.8% | $17.4M+2583.0% | $649K-6.2% | $692K-2.1% | $707K+26.2% | $560K |
| Goodwill | $6.5M+1.1% | $6.4M+23.5% | $5.2M-24.4% | $6.8M+103.7% | $3.4M+3.1% | $3.3M+3.0% | $3.2M-8.5% | $3.5M |
| Total Liabilities | $297.3M+3.0% | $288.7M+22.8% | $235.1M+81.9% | $129.3M+20.2% | $107.6M+138.3% | $45.1M+4.6% | $43.2M+2.5% | $42.1M |
| Current Liabilities | $70.3M-0.1% | $70.4M+115.2% | $32.7M+15.4% | $28.3M+310.3% | $6.9M-15.7% | $8.2M+15.9% | $7.1M-4.9% | $7.4M |
| Long-Term Debt | $5.3M+3.9% | $5.1M+244.0% | $1.5M-4.1% | $1.5M | N/A | N/A | $1.4M | N/A |
| Total Equity | $264.7M-8.4% | $289.0M+41.6% | $204.2M+175.6% | $74.1M+193.6% | $25.2M-40.6% | $42.5M-11.2% | $47.9M+23.8% | $38.7M |
| Retained Earnings | -$272.8M-14.4% | -$238.5M-3.1% | -$231.3M-51.6% | -$152.6M-9.2% | -$139.7M-116.2% | -$64.6M-15.0% | -$56.2M-19.5% | -$47.0M |
ASPI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$23.3M-31.4% | -$17.8M+0.5% | -$17.9M-101.5% | -$8.9M-12.1% | -$7.9M-149.2% | -$3.2M+15.7% | -$3.8M+22.3% | -$4.8M |
| Capital Expenditures | $4.1M-33.4% | $6.1M+155.9% | $2.4M-23.8% | $3.1M+75.0% | $1.8M-22.1% | $2.3M+74.6% | $1.3M-70.5% | $4.5M |
| Free Cash Flow | -$27.4M-14.8% | -$23.9M-18.0% | -$20.2M-68.7% | -$12.0M-23.8% | -$9.7M-77.0% | -$5.5M-7.8% | -$5.1M+45.5% | -$9.3M |
| Investing Cash Flow | $40.0M+141.1% | -$97.2M-29.3% | -$75.2M-4898.9% | -$1.5M+95.3% | -$31.7M-1245.9% | -$2.4M+21.9% | -$3.0M+32.7% | -$4.5M |
| Financing Cash Flow | -$2.5M-105.8% | $43.2M-83.7% | $264.1M+365.8% | $56.7M+11.2% | $51.0M+22769.3% | -$225K-101.3% | $17.7M-45.4% | $32.4M |
| Dividends Paid | N/A | N/A | $0 | $0 | N/A | N/A | $341 | $0 |
Not reported in any period shown, so not listed: Share Buybacks.
ASPI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.9%-11.0pp | 39.9%+27.4pp | 12.5%+3.9pp | 8.6%-39.1pp | 47.8%+18.1pp | 29.7%-21.0pp | 50.7%+23.7pp | 27.0% |
| Operating Margin | -667.5% | -595.4% | -150.2% | -306.1% | -999.1% | -721.6% | -640.7% | -499.5% |
| Net Margin | -663.5% | -170.4% | -380.1% | -263.7% | -6273.5% | -767.9% | -772.5% | -676.2% |
| Return on Equity | -12.8%-10.4pp | -2.5%+28.6pp | -31.0%-13.6pp | -17.4%+280.4pp | -297.9%-278.0pp | -19.9%-0.6pp | -19.3%-0.2pp | -19.0% |
| Return on Assets | -5.9%-4.7pp | -1.2%+11.5pp | -12.7%-7.0pp | -5.7%+49.6pp | -55.3%-46.0pp | -9.3%+0.5pp | -9.8%-1.0pp | -8.7% |
| Current Ratio | 3.87-0.5x | 4.39-7.8x | 12.23+6.1x | 6.14-8.6x | 14.72+7.5x | 7.21-2.1x | 9.31+1.8x | 7.55 |
| Debt-to-Equity | 0.020.0x | 0.020.0x | 0.010.0x | 0.02-4.2x | 4.26+3.2x | 1.06+1.0x | 0.03-1.1x | 1.09 |
| FCF Margin | -535.3% | -571.7% | -121.5% | -245.5% | -809.7% | -497.2% | -425.8% | -857.3% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where ASP Isotopes Ranks
Frequently Asked Questions
What is ASP Isotopes's annual revenue?
ASP Isotopes (ASPI) reported $23.8M in total revenue for fiscal year 2025. This represents a 475.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ASP Isotopes's revenue growing?
ASP Isotopes (ASPI) revenue grew by 475.5% year-over-year, from $4.1M to $23.8M in fiscal year 2025.
Is ASP Isotopes profitable?
No, ASP Isotopes (ASPI) reported a net income of -$159.8M in fiscal year 2025.
What is ASP Isotopes's EBITDA?
ASP Isotopes (ASPI) had EBITDA of -$58.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does ASP Isotopes have?
As of fiscal year 2025, ASP Isotopes (ASPI) had $279.6M in cash and equivalents against $1.5M in long-term debt.
What is ASP Isotopes's gross margin?
ASP Isotopes (ASPI) had a gross margin of 14.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is ASP Isotopes's return on equity (ROE)?
ASP Isotopes (ASPI) has a return on equity of -78.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ASP Isotopes's free cash flow?
ASP Isotopes (ASPI) recorded an outflow of $47.4M in free cash flow during fiscal year 2025. This represents a -79.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ASP Isotopes's operating cash flow?
ASP Isotopes (ASPI) recorded an outflow of $37.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ASP Isotopes's total assets?
ASP Isotopes (ASPI) had $498.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ASP Isotopes's capital expenditures?
ASP Isotopes (ASPI) invested $9.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does ASP Isotopes spend on research and development?
ASP Isotopes (ASPI) invested $12.4M in research and development during fiscal year 2025.
What is ASP Isotopes's current ratio?
ASP Isotopes (ASPI) had a current ratio of 12.23 as of fiscal year 2025, which is generally considered healthy.
What is ASP Isotopes's debt-to-equity ratio?
ASP Isotopes (ASPI) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ASP Isotopes's return on assets (ROA)?
ASP Isotopes (ASPI) had a return on assets of -32.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does ASP Isotopes's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ASP Isotopes (ASPI) held $332.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $37.8M over that year. Dividing the one by the other, the reported balance equals about 106 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is ASP Isotopes's Altman Z-Score?
ASP Isotopes (ASPI) has an Altman Z-Score of 1.40, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ASP Isotopes's Piotroski F-Score?
ASP Isotopes (ASPI) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ASP Isotopes's earnings high quality?
ASP Isotopes (ASPI) reported a net loss of $159.8M while operations used $37.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can ASP Isotopes cover its interest payments?
ASP Isotopes (ASPI) reported an operating loss of $59.9M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is ASP Isotopes?
ASP Isotopes (ASPI) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.